Therapy of Alzheimer's Disease with an antibody against oligomeric pyro-Glu-Abeta peptides
Scientists at the University of Göttingen developed a novel, proprietary antibody for the therapy and/or diagnosis of Alzheimer's Disease (AD) through the targeting of specifically pyro-Glu-Amyloid beta peptides.
Alzheimer's Disease (AD) is the main neurodegenerative disease worldwide affecting more than 29 Mill. people. By 2050 the prevalence will quadruple, by this time 1 in 85 persons worldwide will be living with AD. AD still features high growth potential and room for further innovation due to the huge worldwide growth of the number of patients and the lack of efficacious drugs. The AD market is estimated at 1,6 Mrd US$ for 2015, the main countries affected being USA, Japan and Germany.
We developed a new proprietary, monoclonal antibody against Alzheimer's Disease.
(1) Therapeutic effect: Rescue of behavioral deficits
(2) Reduction of plaque load
Sandwich ELISA with proprietary 9D5 antibody as capturing antibody and 2-48 (anti pyro-Glu-Abeta) as detecting antibody demonstrates reduced levels of plasma levels of pyro-Glu-Abeta peptide oligomers in AD patients (n=16) as compared to non-demented controls (n=10) (unpaired t-test, p<0.05)
Proof of concept (rescue of behavioral deficits) in a mouse animal model.
Granted patents EP2576617B1 (validated in DE, FR, GB) and US8795664B2.
J. Biol. Chem. 2010, 285, 41517-41524, Wirths et al. (J. Biol. Chem. jbc.M110.178707)
Dr. Stefan Uhle